On September 23, an FDA advisory panel voted on Galleri, a blood test proposed for screening adults 50 and older for signals from multiple cancers. The panel’s recommendation is not FDA approval, and it does not settle the biggest question about multi-cancer blood testing: Will finding more signals ultimately help people live longer or avoid advanced cancer?
According to Scientific American’s report on the meeting, the panel voted 10–0 that Galleri was safe, 6–4 that it was effective, and 7–2, with one abstention, that its benefits outweighed its risks. The split effectiveness vote matters. It reflects substantial disagreement about whether the available evidence establishes effectiveness.
For adults considering the Galleri test after 50, the most useful response is not excitement or dismissal. It is a clear look at what the test measures, what a result can mean, and what remains unknown.
The short version
- The advisory vote is nonbinding; FDA has not approved Galleri.
- The proposed use is prescription-only screening for adults 50 and older.
- A positive result is not a cancer diagnosis. It starts a diagnostic workup.
- A negative result does not rule out cancer.
- Galleri does not replace mammograms, colorectal screening, cervical screening, lung screening or other care recommended for you.
- A large randomized trial did not significantly reduce its primary outcome: the combined incidence of stage III and IV cancers.
What changed after the FDA panel vote?
The FDA’s Molecular and Clinical Genetics Panel reviewed GRAIL’s premarket approval application for Galleri on September 23, 2026.
The benefit-risk vote is one input to FDA’s review. It does not authorize the test. FDA explains that its advisory committees offer independent, nonbinding recommendations, and the agency is not legally required to follow them.
That distinction is especially important because some headlines describe the test as clearing a hurdle “on track to approval.” The accurate status is simpler: the panel voted yes on safety and benefit-risk, but the effectiveness vote was divided; FDA must still make the regulatory decision. No final-decision date was announced on the meeting page.
That does not mean Galleri has never been offered. FDA’s briefing says an earlier version was launched in June 2021 and has been available by prescription in the United States despite not having FDA marketing authorization.
The proposed indication is also narrower than “a cancer test for everyone.” Galleri would be a prescription-only screening test for adults 50 or older. It is not being proposed as a way to diagnose symptoms, and the panel vote is not a recommendation that every person over 50 should use it.
What is the Galleri cancer blood test?
Galleri is a multi-cancer detection blood test. It looks for cancer-associated methylation patterns—chemical tags attached to fragments of cell-free DNA circulating in the blood. Software analyzes those patterns and, when a cancer signal is detected, predicts where that signal may have originated in the body.
That predicted “cancer signal origin” is meant to help a clinician decide which diagnostic tests may be appropriate next. It is not a diagnosis by itself.
Even the word “early” remains under discussion. FDA specifically asked the panel whether the available evidence was sufficient to include “early detection” in the proposed indication. That is why it is safer to distinguish multi-cancer signal detection from proof that screening improves outcomes.
According to the FDA briefing materials, the proposed result has two broad possibilities:
- Cancer Signal Detected: Cancer may be present. A qualified healthcare professional should arrange diagnostic follow-up, which may involve imaging, laboratory tests, endoscopy, biopsy or other procedures depending on the predicted origin and the person’s health history.
- No Cancer Signal Detected: The test did not find a signal it recognizes. Cancer can still be present, so routine screening and evaluation of concerning symptoms should continue.
This is a screening test for people without a current clinical suspicion of cancer. If you have concerning symptoms, do not wait for a screening blood test. Seek a diagnostic evaluation.
How accurate is Galleri?
There is no honest single-number answer. “Accuracy” can refer to several different measures, and the results vary by cancer type, stage, study and version of the test.
FDA’s briefing reports three measures from final-Galleri analyses based on stored samples from two studies. These are frozen-sample bridge estimates, not results from prospective use of the final Galleri assay:
| Measure | PATHFINDER 2 | NHS-Galleri | What it means in plain English |
|---|---|---|---|
| 12-month episode sensitivity | 35.0% | 31.6% | Among people diagnosed with cancer during the following 12 months, roughly one-third had a signal detected in this analysis. |
| Specificity | 99.85% | 99.74% | Among people not diagnosed with cancer during follow-up, false-positive signals were uncommon. |
| Positive predictive value | 77.0% | 66.2% | Among positive results in these 12-month analyses, roughly two-thirds to three-quarters were followed by a cancer diagnosis. |
FDA cautions that “episode sensitivity” counts cancers diagnosed over the 12 months after the blood draw. For cancers the test missed, researchers did not necessarily know whether the disease was already present—or at what stage—on the day the blood was taken. Episode sensitivity may therefore differ from true sensitivity at the moment of screening.
These figures come from FDA’s analysis of the final Galleri assay, but there is an important limitation: the trials prospectively used an earlier device called MCED-V2. FDA says the final Galleri test differs in its laboratory workflow, classifier and bioinformatics pipeline. Its performance was estimated by retesting stored frozen samples from selected trial participants, with statistical weighting used for part of the analysis.
Why you may see different Galleri accuracy numbers online
The peer-reviewed PATHFINDER 2 study in Nature Medicine reports different figures for the test used prospectively in that study: 39.3% 12-month episode sensitivity, 99.64% specificity and 60.3% positive predictive value.
Those numbers are not necessarily mistakes. They describe a different device version and analysis from the final-Galleri estimates in FDA’s briefing. Articles that mix the two sets without explaining the difference can make the evidence look more certain than it is.
The practical message is straightforward: high specificity does not mean Galleri finds most cancers. False-positive signals were uncommon in the studies, but many cancers diagnosed during follow-up did not produce a detected signal.
Did Galleri reduce late-stage cancer?
This is the most important unanswered question.
PATHFINDER 2 was a large prospective, single-arm study involving 35,878 adults 50 and older in North America who were not under clinical suspicion for cancer. The study prospectively used MCED-V2 and reported performance and safety descriptively, without hypothesis testing. It showed that multi-cancer testing can identify some cancers and return a predicted origin for a detected signal. It was not a randomized trial designed to prove that screening reduces advanced disease or deaths.
A separate randomized trial in England came closer to that question. The NHS-Galleri trial assigned 142,250 adults aged 50 to 77 to intervention and control groups. Like PATHFINDER 2, it prospectively used MCED-V2 rather than the final Galleri assay.
After three rounds, MCED-V2 screening did not significantly reduce the trial’s primary outcome: the combined incidence of stage III and IV cancers among 12 prespecified cancer types. The incidence rate ratio was 1.03, with a 95% confidence interval of 0.92 to 1.14.
Stage IV cancer alone was a secondary outcome. That analysis produced an incidence rate ratio of 0.86, with a confidence interval of 0.74 to 1.00. The result is uncertain: it does not overturn the negative primary endpoint or prove that the test prevents advanced cancer.
Longer follow-up is needed to answer the question patients care about most: whether multi-cancer screening reduces cancer deaths without creating disproportionate harm. Trial-related adverse events were reported in fewer than 1% of NHS-Galleri participants, and none were serious; that figure does not capture every possible downstream burden of diagnostic workup in routine practice.
Both major studies were funded by GRAIL. OHSU’s disclosure says GRAIL designed and funded PATHFINDER 2 and participated in data curation, analysis, interpretation, and manuscript drafting and approval. Industry funding does not invalidate a study, but it is relevant when weighing evidence—especially when the randomized primary outcome was negative.
What are the possible benefits and harms?
The appeal is easy to understand. One blood draw could detect signals from some cancers for which there is no established population screening program.
Potential benefits include:
- detecting some cancer signals in a screening population without clinical suspicion;
- directing follow-up toward a likely organ or tissue;
- adding a screening option for cancers without routine population tests; and
- offering a relatively simple first step through a blood draw.
The trade-offs deserve equal attention:
- Missed cancers: A negative result can create false reassurance if it leads someone to ignore symptoms or skip proven screening.
- False-positive signals: Even an uncommon false positive may lead to imaging, invasive procedures, expense and anxiety.
- Uncertain benefit: Detecting more cancer is not automatically the same as preventing late-stage disease or death.
The American Cancer Society’s current guidance says multi-cancer tests do not diagnose cancer, should not replace established screening and do not yet have official US clinical-practice recommendations for routine use.
Why regular cancer screening still matters after 50
Galleri’s proposed label explicitly says that a negative result does not rule out cancer and that people should continue guideline-recommended single-cancer screening.
That means the test is not an alternative to a mammogram, colorectal screening, cervical screening, appropriate lung screening or a clinician-guided conversation about prostate cancer. Those established approaches have their own eligibility rules and evidence bases. Your schedule can depend on age, sex, smoking history, family history, previous results and country or province.
New technology can be valuable, but it should not crowd out the health actions that already have stronger evidence. That is one reason proven health basics still matter, even when a new test sounds simpler.
Seven questions to ask before considering the Galleri test after 50
If you are interested in Galleri, bring these questions to a clinician who knows your health history:
- Am I actually in the population studied and proposed for this test? Age 50 is only one factor; symptoms, recent cancer, inherited risk and other conditions can change the conversation.
- Am I up to date on established screening? A new blood test should not become a reason to postpone proven screening.
- What would happen after a positive result? Ask who would coordinate follow-up, which tests might come next and how long diagnostic resolution could take.
- What costs might follow the first blood draw? Consider the test, imaging, specialist visits, procedures and insurance coverage—not just the initial price.
- How should I respond to a negative result? The answer should include continuing routine screening and investigating symptoms.
- How do my personal risks change the balance? Family history, smoking, previous cancer and genetic risk may affect which screening or diagnostic pathway is most useful.
- How comfortable am I with uncertainty? Some people value the chance of finding a difficult-to-screen cancer; others place more weight on possible follow-up procedures and unresolved outcome evidence.
For any complex health visit, it can help to prepare a focused list of medicines, questions and priorities before the appointment.
What should Canadian readers know?
The September 23 vote concerns a US FDA application. It is not a Health Canada decision and does not change provincial screening guidance.
In its briefing materials for the meeting, FDA said Galleri had not received marketing authorization in the United States or any foreign country. Because regulatory status can change, Canadian readers should verify current local availability and authorization and continue screening recommended by their provincial program and healthcare professional.
The bottom line
The Galleri FDA panel vote is important, but it is not the finish line.
The evidence suggests that multi-cancer blood testing can find signals from some cancers while producing relatively few false-positive signals in studied populations. The same evidence also shows why caution is necessary: sensitivity is limited, a negative result cannot rule out cancer, the final assay was bridged from stored samples, and the largest randomized trial did not meet its primary late-stage cancer endpoint.
For now, Galleri is not proven to improve long-term outcomes. Adults over 50 can follow the FDA decision, keep up with established screening and discuss the trade-offs with a qualified clinician—without treating the advisory vote as approval or a positive result as a diagnosis.
Frequently Asked Questions
Is the Galleri test FDA approved?
No. Independent meeting coverage reports that the panel voted 10–0 on safety, 6–4 on effectiveness, and 7–2 with one abstention on benefit-risk. Those advisory votes are nonbinding; FDA must still decide whether to grant marketing authorization.
Who is the Galleri test proposed for?
The proposed indication is prescription-only screening for adults aged 50 or older. That is an intended-use population, not a recommendation that every adult over 50 should take the test.
Does Galleri diagnose cancer?
No. A Cancer Signal Detected result means diagnostic follow-up is needed. Imaging, laboratory testing, endoscopy, biopsy or another procedure may be required to determine whether cancer is present.
What does a negative Galleri result mean?
It means the test did not detect a cancer-associated signal it recognizes. It does not prove that you are cancer-free, and it should not change recommended screening or delay evaluation of symptoms.
Can Galleri replace a mammogram, colon cancer screening or lung screening?
No. FDA’s proposed labeling and the American Cancer Society both say people should continue established single-cancer screening.
Has Galleri been shown to reduce cancer deaths?
Not yet. The large NHS-Galleri randomized trial did not significantly reduce its primary combined stage III/IV cancer endpoint. Longer follow-up is needed to assess cancer mortality.
Why do published Galleri accuracy figures differ?
The trials prospectively used an earlier test called MCED-V2. FDA estimated final Galleri performance by retesting stored samples and using a partly weighted analysis. Figures can also vary by cancer type, stage, follow-up period and the metric being reported.
Sources
- FDA: September 23, 2026 advisory committee meeting record
- FDA executive summary for Galleri
- PATHFINDER 2 in Nature Medicine
- NHS-Galleri randomized trial in The New England Journal of Medicine
- American Cancer Society: Multi-cancer early detection tests
- Scientific American: FDA panel vote report
- OHSU PATHFINDER 2 report and funding disclosures
Accuracy note: This article distinguishes the prospectively studied MCED-V2 device from FDA’s frozen-sample bridge analysis of final Galleri. Regulatory status and guidance may change; the article should be rechecked when FDA announces a final decision. This information is educational and is not a substitute for personal medical advice.